Print this article

Quality by Design.

Keywords: ,

e-version image

Click HERE to download the PDF version



Current state-of-the-art large-scale pharmaceutical peptide manufacturing: expensive, time consuming and non-sustainable
Today, the vast majority of peptides are synthesized by straight-through solid-phase peptide synthesis (SPPS). During SPPS side-products accumulate often resulting in challenging HPLC purification and low overall yield. Although higher yields can be obtained using a fragment condensation strategy, an SPPS-LPPS hybrid fragment approach is often not feasible due to racemization, the poor solubility of the fully protected fragments and the formation of additional by-products due to